In the phase Ib KEYNOTE trial, the use of pembrolizumab (anti PD-1) in monotherapy was studied in TC including PTC and FTC showing an ORR of 9% and reduction of tumor size of 35–50% [129]. This evidence concerns the gene PDCD1 and neoplasm.